Summary
Alexander Brandt is an executive director in neuroscience and clinical drug developer with over 15 years of experience translating neurobiology into therapies for disorders like multiple sclerosis and ALS, with a particular emphasis on genetic medicines. He combines clinician training (M.D.) with deep expertise in translational medicine, neuroimaging, and neuroimmunology, bridging academic research and industry drug development. Currently leading neuroscience efforts at Eli Lilly while holding a visiting professorship and longstanding ties to Charité and UC Irvine, he has repeatedly moved ideas from bench to clinic and into startup practice as a former CEO. His background in neuroimaging science underpins data-driven biomarker strategies that de-risk trials and accelerate decision making. Based in Munich and active across transatlantic collaborations, he pairs entrepreneurial instincts with rigorous clinical science to advance precision therapies for neurologic disease. An engineer and developer on GitHub in his spare time, he brings a rare mix of hands-on technical curiosity to leadership in biopharma.
11 years of coding experience
3 years of employment as a software developer
Medicine, Medicine at The University of Freiburg
Doctor of Medicine (M.D.), Medizin, M.D., Doctor of Medicine (M.D.), Medizin, M.D. at Charité - Universitätsmedizin Berlin
German, English